BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis (vol 13, 838449, 2022)

被引：3
|
作者：
Herrmann, Franziska Elena [1 ]
Hesslinger, Christian [1 ]
Wollin, Lutz [1 ]
Nickolaus, Peter [1 ]
机构：
[1] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach An Der Riss, Germany
来源：
FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷
关键词：
PDE4B; IPF; lung fibrosis; phosphodiesterase; cAMP; ILDs;
D O I：
10.3389/fphar.2023.1219760
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：2
相关论文
共 19 条
  • [1] BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
    Herrmann, Franziska Elena
    Hesslinger, Christian
    Wollin, Lutz
    Nickolaus, Peter
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)
    Sgalla, Giacomo
    Simonetti, Jacopo
    Cortese, Stefania
    Richeldi, Luca
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (01) : 17 - 23
  • [3] Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)
    Frutos, Rogelio P.
    Tampone, Thomas G.
    Gerstmann, Frank
    Weber, Dirk
    Brodmann, Tobias
    Hagenko''tter, Robert
    Abella, Jocelyn
    Yang, Bing-Shiou
    Mulder, Jason
    Rodriguez, Sonia
    Lee, Heewon
    Gao, Joe
    Song, Jinhua J.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2024, 28 (09) : 3745 - 3751
  • [4] Effect of BI 1015550, a preferential PDE4B inhibitor, on gene expression profiles and lung function in IPF
    Richeldi, Luca
    Roy, Janine
    Schmid, Ramona
    Hesslinger, Christian
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [5] Preferential PDE4B Inhibition - A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis
    Chambers, Rachel C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23): : 2235 - 2236
  • [6] Effect of BI 1015550, a preferential PDE4B inhibitor, on FEV1/FVC ratio in IPF
    Koschel, D.
    Cottin, V
    Azuma, A.
    Maher, T.
    Valenzuela, C.
    Wijsenbeek, M.
    Liu, Y.
    Stowasser, S.
    Zoz, D.
    Richeldi, L.
    PNEUMOLOGIE, 2024, 78 : S82 - S82
  • [7] Effect of BI 1015550, a preferential PDE4B inhibitor, on FEV1/FVC ratio in IPF
    Cottin, Vincent
    Azuma, Arata
    Maher, Toby M.
    Valenzuela, Claudia
    Wijsenbeek, Marlies S.
    Liu, Yi
    Stowasser, Susanne
    Zoz, Donald F.
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [8] Staying in the Flow: Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) Improves Features of Vascular Dysfunction in Lung Fibrosis In Vitro and In Vivo
    Reininger, D.
    Wolf, F.
    Mayr, C. H.
    Nickolaus, P.
    Herrmann, F. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [9] Baseline Characteristics of Patients Enrolled in FIBRONEER™-IPF, A Phase III Randomized Placebo-controlled Trial of the Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) in Patients With Idiopathic Pulmonary Fibrosis
    Richeldi, L.
    Assassi, S.
    Azuma, A.
    Cottin, V.
    Hoffmann-Vold, A. M.
    Kreuter, M.
    Liu, Y.
    Maher, T. M.
    Oldham, J. M.
    Stowasser, S.
    Valenzuela, C.
    Wijsenbeek, M. S.
    Zoz, D. F.
    Martinez, F. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [10] Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
    Richeldi, Luca
    Azuma, Arata
    Cottin, Vincent
    Hesslinger, Christian
    Stowasser, Susanne
    Valenzuela, Claudia
    Wijsenbeek, Marlies S.
    Zoz, Donald F.
    Voss, Florian
    Maher, Toby M.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022,
12